Drug intelligence / Profile preview

PANK-003

Development stage: Phase 2
Lead developer: Shenzhen Celconta Life Science
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Injection

Overview

PANK-003 is an investigational cell therapy composed of allogeneic natural killer (NK) cells derived from peripheral blood. It is being developed for the treatment of solid tumors and is currently in Phase 1 clinical trials. The therapy involves the administration of these NK cells in combination with standard adjuvant chemotherapy following surgical resection of tumors. The approach leverages the cytotoxic activity of NK cells to target and eliminate residual cancer cells, potentially improving outcomes when used alongside conventional chemotherapy. The drug utilizes a PB-NK technology platform and is administered via injection[1][2][4].

Beyond the preview

Go deeper on PANK-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PANK-003.

Explore the full profile